<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><description>佰傲谷致力于打造一个垂直于生物制品领域的第三方平台。为生物制药企业提供品牌推广、技术咨询、项目交易、企业合作、人才培养等服务。为生物制药行业从业人员提供沟通交流、会议培训、工作求职、个人展示平台。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sat, 06 Feb 2021 13:31:18 +0800</pubDate><image><url>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</url><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>阿斯利康durvalumab在头颈癌中未达标，中国死亡率达52%</title><link>https://mp.weixin.qq.com/s/I4KYlY5Ugh1e6oZ3nTvLjA</link><description></description><content:encoded><![CDATA[阿斯利康durvalumab在头颈癌中未达标，中国死亡率达52%]]></content:encoded><pubDate>Sat, 06 Feb 2021 12:16:24 +0800</pubDate></item><item><title>原FDA专家谈国内法规修订原则及中美双报发展趋势</title><link>https://mp.weixin.qq.com/s/P6dYebMWW3eYZB28qp7GLw</link><description></description><content:encoded><![CDATA[原FDA专家谈国内法规修订原则及中美双报发展趋势]]></content:encoded><pubDate>Sat, 06 Feb 2021 12:16:24 +0800</pubDate></item><item><title>跌跌撞撞终入局--百时美施贵宝CD19-CAR-T疗法获FDA批准上市</title><link>https://mp.weixin.qq.com/s/v2n7Wa0ciNBal9Bc3iCXdg</link><description></description><content:encoded><![CDATA[跌跌撞撞终入局--百时美施贵宝CD19-CAR-T疗法获FDA批准上市]]></content:encoded><pubDate>Sat, 06 Feb 2021 12:16:24 +0800</pubDate></item><item><title>好消息不断，诺诚健华BTK抑制剂奥布替尼，泛FGFR抑制剂ICP-192均取得临床进展</title><link>https://mp.weixin.qq.com/s/nU0Yrg-bCXy71_e1WC7mjg</link><description></description><content:encoded><![CDATA[好消息不断，诺诚健华BTK抑制剂奥布替尼，泛FGFR抑制剂ICP-192均取得临床进展]]></content:encoded><pubDate>Sat, 06 Feb 2021 12:16:24 +0800</pubDate></item><item><title>“土耳其91.25%，巴西50.65%” 科兴公布新冠灭活疫苗III期临床初步分析</title><link>https://mp.weixin.qq.com/s/OEluxRPSDkxbL-F1K0m4ig</link><description></description><content:encoded><![CDATA[“土耳其91.25%，巴西50.65%” 科兴公布新冠灭活疫苗III期临床初步分析]]></content:encoded><pubDate>Sat, 06 Feb 2021 12:16:24 +0800</pubDate></item><item><title>最新进展！TG-Bio第二届免疫治疗技术大会4月申城亮相！</title><link>https://mp.weixin.qq.com/s/TD7AvqotZ_So1CPmdPJrFA</link><description></description><content:encoded><![CDATA[最新进展！TG-Bio第二届免疫治疗技术大会4月申城亮相！]]></content:encoded><pubDate>Sat, 06 Feb 2021 12:16:24 +0800</pubDate></item><item><title>罗氏终止若干个2020年临床试验失败的中晚期项目</title><link>https://mp.weixin.qq.com/s/-6Me9d_ctQMWmvEQ5Io8wg</link><description></description><content:encoded><![CDATA[罗氏终止若干个2020年临床试验失败的中晚期项目]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:10:15 +0800</pubDate></item><item><title>恒瑞JAK抑制剂治疗溃疡性结肠炎全球II期临床达到主要终点</title><link>https://mp.weixin.qq.com/s/Zq49VhV6lXyhZ02VKJF7lw</link><description></description><content:encoded><![CDATA[恒瑞JAK抑制剂治疗溃疡性结肠炎全球II期临床达到主要终点]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:10:15 +0800</pubDate></item><item><title>如何提升国内药品质量管理，实现国际并轨？FDA、NMPA如是说</title><link>https://mp.weixin.qq.com/s/sbVHoOi5glyez-9xFcF8zA</link><description></description><content:encoded><![CDATA[如何提升国内药品质量管理，实现国际并轨？FDA、NMPA如是说]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:10:15 +0800</pubDate></item><item><title>海和药物提交科创板上市申请，拟募资31.5亿元</title><link>https://mp.weixin.qq.com/s/0oe3ehgSDZoGA702yJHm0A</link><description></description><content:encoded><![CDATA[海和药物提交科创板上市申请，拟募资31.5亿元]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:10:15 +0800</pubDate></item><item><title>安进2020财报：总收入254亿美元！5款药物研发亮红灯</title><link>https://mp.weixin.qq.com/s/4267A7wOrtfsRvwhyCqoGw</link><description></description><content:encoded><![CDATA[安进2020财报：总收入254亿美元！5款药物研发亮红灯]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>GSK加倍下注mRNA技术，1.8亿美元寻找下一代COVID-19疫苗</title><link>https://mp.weixin.qq.com/s/f30jeq0ZNMRiFxbSkVlGig</link><description></description><content:encoded><![CDATA[GSK加倍下注mRNA技术，1.8亿美元寻找下一代COVID-19疫苗]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>多地上市成药企潮流，贝达药业港股上市申请获证监会受理</title><link>https://mp.weixin.qq.com/s/iiSdBWg11klpHn-dTFgVfg</link><description></description><content:encoded><![CDATA[多地上市成药企潮流，贝达药业港股上市申请获证监会受理]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>科兴新冠灭活疫苗附条件上市申请获国家药监局受理</title><link>https://mp.weixin.qq.com/s/BhuHJTB9MQy-7vO29miFMQ</link><description></description><content:encoded><![CDATA[科兴新冠灭活疫苗附条件上市申请获国家药监局受理]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>股价被腰斩，Immunovant公司宣布终止抗FcRn抗体临床研究</title><link>https://mp.weixin.qq.com/s/eVRCiFICMklNHaMn3-axQQ</link><description></description><content:encoded><![CDATA[股价被腰斩，Immunovant公司宣布终止抗FcRn抗体临床研究]]></content:encoded><pubDate>Wed, 03 Feb 2021 12:24:56 +0800</pubDate></item><item><title>信达生物PD-1单抗在华获批NSCLC领域适应症</title><link>https://mp.weixin.qq.com/s/jTTMbmpgneqtpKJuanvpmg</link><description></description><content:encoded><![CDATA[信达生物PD-1单抗在华获批NSCLC领域适应症]]></content:encoded><pubDate>Wed, 03 Feb 2021 12:24:56 +0800</pubDate></item><item><title>高瓴26亿入股诺诚健华！誓要集齐中国生物医药“七龙珠”</title><link>https://mp.weixin.qq.com/s/ma07O4niBq7htv7OzV8KlA</link><description></description><content:encoded><![CDATA[高瓴26亿入股诺诚健华！誓要集齐中国生物医药“七龙珠”]]></content:encoded><pubDate>Wed, 03 Feb 2021 12:24:56 +0800</pubDate></item><item><title>靶向IL-6疗法的十年</title><link>https://mp.weixin.qq.com/s/xLxIxO3w1JUlyxRHwBmZ2Q</link><description></description><content:encoded><![CDATA[靶向IL-6疗法的十年]]></content:encoded><pubDate>Tue, 02 Feb 2021 16:46:42 +0800</pubDate></item><item><title>股价涨幅超7%，君实生物与Coherus达成70亿元合作</title><link>https://mp.weixin.qq.com/s/QAXOSotrG2ecK_sOdv22Ew</link><description></description><content:encoded><![CDATA[股价涨幅超7%，君实生物与Coherus达成70亿元合作]]></content:encoded><pubDate>Tue, 02 Feb 2021 16:46:42 +0800</pubDate></item><item><title>转战新阵地，拓宽适应症：新冠背景下的干扰素市场分析</title><link>https://mp.weixin.qq.com/s/baS2n5hhe7O1-_8VsC_tyw</link><description></description><content:encoded><![CDATA[转战新阵地，拓宽适应症：新冠背景下的干扰素市场分析]]></content:encoded><pubDate>Mon, 01 Feb 2021 12:41:34 +0800</pubDate></item></channel></rss>